
    
      This is a single center, placebo-controlled, single blinded dose escalation study to
      preliminarily assess the safety, reactogenicity, and immunogenicity of different HAC1 vaccine
      formulations. This study will assess a novel HAC1 vaccine, which is plant derived. This
      vaccine will be compared to Placebo of normal (0.9%) saline, and reference vaccine consisting
      of an approved monovalent vaccine containing an A/California (H1N1)-like strain.

      Subjects will receive 2 intramuscular injections of the experimental vaccine, placebo, or
      reference vaccine on Study Days 0 and 21
    
  